The demo accomplished equally its Most important endpoints, with semaglutide two.four mg demonstrating statistically significant and top-quality improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH when compared with placebo.1What